A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Trial Details

NCT ID
NCT06496178
Phase
PHASE3
Sponsor
Merus B.V.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Petosemtamab
  • Investigator's Choice
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Prescott, Arizona, United States|34.54002,-112.4685
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Duarte, California, United States|34.13945,-117.97729
  • La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

  • Signed ICF before initiation of any study procedures.
  • Age ≥ 18 years at signing of ICF.
  • Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative in…
  • HNSCC participants progressed on or after anti-PD-1 therapy and platinum-containing therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →